| |
| |
|
| Insider
Information: |
Davis Aaron I. |
| Relationship: |
Director |
| City: |
Solana Beach |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
17,915,051 |
|
|
Indirect Shares
|
11,622,846 |
|
|
| Direct
Value |
$7,622,427,600 |
|
|
|
Indirect Value
|
$78,903,219,053 |
|
|
| Total
Shares |
29,537,897 |
|
|
| Total
Value |
$86,525,646,653 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
9
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
9
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
-9.0
|
-5.0
|
| Percentage
Gain/Loss : |
 -78.4%
|
-165.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Odonate Therapeutics Inc |
ODT |
Director, 10% Owner |
2021-11-19 |
445,756 |
2021-11-19 |
4,607,086 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2019-01-08 |
2,079,190 |
Premium* |
|
|
Iteos Therapeutics, Inc. |
ITOS |
|
2023-08-23 |
1,804,058 |
2022-05-11 |
2,154,058 |
Premium* |
|
|
Pmv Pharmaceuticals, Inc. |
PMVP |
Former 10% Owner |
2020-09-29 |
2,268,236 |
2020-09-29 |
60,837 |
Premium* |
|
|
Tyra Biosciences, Inc. |
TYRA |
|
2024-02-06 |
6,448,359 |
2024-02-06 |
85,939 |
Premium* |
|
|
Tango Therapeutics Ord Shs |
TNGX |
|
2023-10-09 |
6,948,642 |
2024-05-03 |
488,524 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
Director |
2024-01-26 |
0 |
2022-11-04 |
2,147,212 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • • |
2020-07-28 |
4 |
B |
$19.00 |
$27,075,000 |
I/I |
1,425,000 |
72,243 |
2.25 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,992,259 |
48,691 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-01-03 |
4 |
S |
$47.63 |
$24,677,379 |
D/D |
(515,323) |
46,477 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-01-04 |
4 |
S |
$41.84 |
$7,898,264 |
D/D |
(184,677) |
0 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-03-22 |
4 |
B |
$31.88 |
$968,509 |
I/I |
30,000 |
3,172,058 |
2.1 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-03-23 |
4 |
B |
$32.85 |
$656,980 |
I/I |
20,000 |
3,192,058 |
2.1 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-04-28 |
4 |
S |
$27.40 |
$4,110,315 |
I/I |
(150,000) |
3,042,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-04-29 |
4 |
S |
$27.01 |
$3,388,822 |
I/I |
(125,000) |
2,917,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-05-02 |
4 |
S |
$26.91 |
$2,748,734 |
I/I |
(100,000) |
2,817,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-05-09 |
4 |
S |
$22.91 |
$5,265,843 |
I/I |
(225,000) |
2,592,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-05-10 |
4 |
S |
$24.77 |
$2,515,970 |
I/I |
(100,000) |
2,492,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
Director |
– • – |
2022-05-11 |
4 |
S |
$17.53 |
$6,167,422 |
I/I |
(338,000) |
2,154,058 |
0 |
- |
|
| ITOS |
Iteos Therapeutics, Inc. |
See remarks |
• • – |
2023-08-23 |
4 |
S |
$14.19 |
$5,692,673 |
D/D |
(350,000) |
1,804,058 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • • |
2019-01-07 |
4 |
S |
$45.47 |
$1,855,803 |
D/D |
(40,000) |
47,052 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • • |
2019-01-08 |
4 |
S |
$52.20 |
$528,000 |
D/D |
(10,000) |
37,052 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • • |
2020-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
39,052 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • • |
2021-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,475 |
40,527 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • • |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,546 |
43,073 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • • |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,444 |
47,517 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
54,325 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(54,325) |
0 |
0 |
- |
|
| ODT |
Odonate Therapeutics Inc |
Director |
– • • |
2017-12-06 |
4 |
B |
$24.00 |
$9,999,984 |
I/I |
416,666 |
2,726,938 |
2.25 |
- |
|
| ODT |
Odonate Therapeutics Inc |
Director |
– • • |
2018-03-22 |
4 |
B |
$20.94 |
$490,143 |
I/I |
23,407 |
2,750,345 |
2.25 |
- |
|
| ODT |
Odonate Therapeutics Inc |
Director |
– • • |
2018-03-23 |
4 |
B |
$23.96 |
$1,028,914 |
I/I |
42,943 |
2,793,288 |
2.25 |
- |
|
| ODT |
Odonate Therapeutics Inc |
Director |
– • • |
2018-03-26 |
4 |
B |
$22.41 |
$754,097 |
I/I |
33,650 |
2,826,938 |
2.25 |
- |
|
64 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
